Boston Scientific (NYSE:BSX) Issues Q3 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its third quarter 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.800-0.820 for the period, compared to the consensus earnings per share estimate of 0.840. The company issued revenue guidance of $5.2 billion-$5.3 billion, compared to the consensus revenue estimate of $5.4 billion. Boston Scientific also updated its FY 2026 guidance to 3.280-3.320 EPS.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $46.04 on Wednesday. The company’s fifty day moving average price is $46.78 and its 200-day moving average price is $63.10. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The firm has a market capitalization of $68.44 billion, a price-to-earnings ratio of 19.27, a PEG ratio of 0.87 and a beta of 0.58. Boston Scientific has a one year low of $42.20 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.36 billion. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts anticipate that Boston Scientific will post 3.35 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a stock repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of recent research reports. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. Stifel Nicolaus reduced their price target on shares of Boston Scientific from $75.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, June 25th. Jefferies Financial Group decreased their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Piper Sandler restated an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Finally, Evercore set a $65.00 price objective on shares of Boston Scientific in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $78.40.

Insider Activity

In related news, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the transaction, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 9,800 shares of company stock valued at $554,012. Insiders own 0.34% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Boston Scientific reported adjusted EPS of $0.86, above the $0.83 consensus estimate, while revenue reached $5.442 billion versus expectations of $5.36 billion. Sales increased 7.5% year over year, supported by 8.3% growth in Cardiovascular and 5.9% growth in MedSurg. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: Share repurchases and strategic investment added support. The company completed its $2 billion accelerated share-repurchase program, buying approximately 40 million shares. It also invested $1.5 billion in MiRus LLC for a roughly 34% stake and an option to acquire its TAVR business, expanding Boston Scientific’s cardiovascular growth opportunities.
• Positive Sentiment: Product development remained constructive. Boston Scientific received FDA 510(k) clearance for its TruSelect 2.6 Microcatheter, while continued progress in its FARAFLEX atrial-fibrillation study could strengthen its position in pulsed-field ablation.
• Neutral Sentiment: Management launched a multiyear restructuring program. The plan is expected to cost $700 million to $800 million through 2029 and may include headcount reductions. Management expects the initiative to reduce annual costs by approximately $500 million, but the near-term expenses and job cuts introduce execution risk. Boston Scientific unveils new restructuring plan
• Negative Sentiment: Full-year and third-quarter guidance trailed analysts’ expectations. Boston Scientific forecast third-quarter adjusted EPS of $0.80–$0.82 and revenue of $5.2–$5.3 billion, below consensus estimates of $0.84 and $5.4 billion. Full-year adjusted EPS guidance of $3.28–$3.32 and revenue guidance of $21.2–$21.4 billion also fell short of consensus estimates of $3.36 and $21.6 billion.
• Negative Sentiment: Analysts have reduced valuation targets. UBS lowered its price target to $74 from $95 while maintaining a Buy rating, and Oppenheimer cut its target to $85 from $90 while retaining an Outperform rating. These reductions suggest analysts remain positive on the long-term story but see less near-term upside.

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BSX. Garton & Associates Financial Advisors LLC bought a new stake in Boston Scientific in the 4th quarter worth $26,000. Swiss RE Ltd. bought a new position in shares of Boston Scientific during the fourth quarter valued at about $26,000. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Sfam LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth about $29,000. Finally, Pin Oak Investment Advisors Inc. bought a new stake in shares of Boston Scientific in the third quarter worth about $41,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.